Nuvaring Insert, Extended Release
Product Images NDC 78206-146

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Nuvaring (NDC 78206-146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Organon Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Nuvaring 01)

A horizontal bar chart showing the estimated range of women with a blood clot out of 10,000 woman-years for different user groups: Non-CHC users who are non-pregnant, CHC users, pregnant women, and postpartum women at 12 weeks only. The x-axis represents the number of women with a blood clot, ranging from 0 to 70.*

FDA Label Image

Nuvaring 01a

A forest plot chart depicting effect estimates (OR, RR, HR) with confidence intervals comparing contraceptive use versus non-use. Study names and years are listed on the left; effect estimates and 95% confidence intervals are visualized as points and horizontal lines on the right, plotted along an Effect Estimate axis ranging approximately from -1.50 to 2.00.*

FDA Label Image

Chemical Structure (Nuvaring 02)

Chemical structures of the active ingredients etonogestrel and ethinyl estradiol, showing their molecular formulas C22H28O2 and C20H24O2, respectively.*

FDA Label Image

Figure 2 (Nuvaring 03)

A line chart depicting plasma concentrations of etonogestrel and ethinyl estradiol (EE) over 21 days following NuvaRing insertion. The x-axis shows days after NuvaRing insertion from 0 to 21, while the y-axes indicate etonogestrel concentration in pg/mL and EE concentration in pg/mL. The graph shows etonogestrel levels rising sharply and plateauing, while EE levels remain stable and lower throughout.*

FDA Label Image

Figure 3 (Nuvaring 04)

An illustration showing contraceptive effectiveness by pregnancies per 100 women per year. It ranks methods from fewer pregnancies (implants, injections, intrauterine devices, sterilization) to more pregnancies (no birth control). Mid-level effectiveness includes birth control pills, skin patch, and vaginal ring with hormones, followed by condoms and diaphragm, then behavioral methods like abstinence during fertile days, spermicide, and withdrawal.*

FDA Label Image

Figure 4 (Nuvaring 05)

A horizontal bar chart comparing the number of women with a blood clot per 10,000 woman-years across four groups: Non-CHC users who are non-pregnant, CHC users, pregnant women, and postpartum women (12 weeks only). The chart shows risk ranges for each group, with postpartum women having the highest range, followed by pregnant women, CHC users, and the lowest for non-CHC non-pregnant users.*

FDA Label Image

Figure A, Figure B, Figure C (Nuvaring 06)

Illustration showing three different body positions for NuvaRing vaginal insert placement. Figure A depicts a lying down position with knees bent. Figure B shows a squatting position. Figure C illustrates standing with one foot elevated on a step. The images guide insertion technique for the extended-release vaginal insert.*

FDA Label Image

Figure D, Figure E (Nuvaring 07)

Illustrations showing hands holding the NuvaRing contraceptive vaginal ring. Figure D depicts a hand holding the ring by a side, while Figure E shows a hand compressing the ring to a smaller size, likely demonstrating insertion technique.*

FDA Label Image

Figure F (Nuvaring 08)

An anatomical diagram illustrating the female reproductive system with labels indicating the uterus, vagina, and the placement of the NuvaRing vaginal insert inside the vagina.*

FDA Label Image

Figure G (Nuvaring 09)

An instructional diagram showing the insertion of a vaginal ring contraceptive. The image depicts a hand placing the NuvaRing vaginal insert inside the vaginal canal, demonstrating the proper positioning of the extended-release contraceptive device.*

FDA Label Image

Figure H (Nuvaring 10)

An instructional illustration showing the vaginal insertion of the NuvaRing contraceptive device. The diagram depicts a sagittal cross-section of female pelvic anatomy, with the NuvaRing positioned inside the vaginal canal near the cervix, indicating correct placement for use.*

FDA Label Image

Figure I (Nuvaring 11)

A black and white anatomical illustration showing the female pelvic region with a vaginal insert positioned inside the vaginal canal. The image likely demonstrates the correct placement of the NuvaRing vaginal insert within the female reproductive anatomy.*

FDA Label Image

Figure J (Nuvaring 12)

An instructional anatomical illustration showing the proper placement of the NuvaRing vaginal insert inside the female reproductive tract. The hand is positioning the ring within the vaginal canal near the cervix, demonstrating correct usage for the etonogestrel and ethinyl estradiol contraceptive insert by Organon LLC.*

FDA Label Image

Principle Display Panel (3 Ring Pouch Carton)

NuvaRing insert packaging label for etonogestrel and ethinyl estradiol vaginal ring delivering 0.120 mg/0.015 mg per day. The label includes storage instructions to refrigerate 2-8°C, warnings to keep out of reach of children, and statements that it is for vaginal use and prescription only. The package contains 3 rings and is labeled with Organon LLC as the manufacturer. Barcode and tamper evident seal locations are noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.